SciMagix, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SciMagix, Inc - overview
Established
1998
Location
Redwood City, CA, US
Primary Industry
Pharmaceuticals
About
SciMagix, Inc is a dynamic company specializing in unique content and experiences across various sectors, including entertainment, lifestyle, and education, aimed at enhancing user engagement and satisfaction. Founded in 1998 and headquartered in Redwood City, US, SciMagix, Inc focuses on delivering innovative solutions to its clientele. The company has successfully raised a total of USD 25. 00 mn through its latest funding round, Series C, which took place on July 30, 2001.
Notable investors in this round included EuclidSR Partners and First Capital. SciMagix had previously engaged in two significant funding deals. SciMagix offers a diverse range of products and services designed to meet consumer demands within the marketplace. The company specializes in delivering unique content and experiences that engage users, primarily targeting the entertainment, lifestyle, and educational sectors.
SciMagix serves urban centers throughout the UK and has expanded its reach to international markets, including Europe and North America, providing memorable user experiences. Revenue generation at SciMagix is structured around subscription models and direct service offerings for both businesses and consumers. Clients can engage in annual or monthly subscription plans for access to services and exclusive content. Their transactions are facilitated through an online platform, allowing users to select tailored packages tailored to their interests, supporting a steady revenue stream.
In July 2001, SciMagix, Inc raised USD 25. 00 mn in Series C funding, co-led by Dresdner Kleinwort Capital and EuclidSR Partners. The company plans to utilize this capital for upcoming product launches and expansions into new geographic regions. Specific markets targeted for expansion include additional urban centers in Europe and North America, with anticipated launches scheduled for the next fiscal year.
This funding will bolster product development and enhance market penetration strategies.
Current Investors
Tullis Health Investors, Band of Angels, Tenex Medical Investors
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.scimagix.com
Company Stage
Series C/Round 3
Total Amount Raised
Subscriber access only
SciMagix, Inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.